Journal of Pharmacovigilance

Reasons for underreporting Adverse Drug Reactions: A review

3^rd International Conference and Exhibition on Pharmacovigilance & Clinical Trials

October 27-29, 2014 Hyderabad International Convention Centre, India

Bhavana Akula, D Giriraja Sekhar, Manasa Rekha and C Gopinath

Posters: J Pharmacovigilance

Abstract:

The purpose of this review is to know the reasons for under reporting of Adverse Drug Reactions (ADR?s) to spontaneous reporting systems. Adverse Drug Reactions are significant cause of morbidity and mortality, and contribute to incidence of adverse events. Most medicines would have been tested for short term safety and efficacy on a limited number of selected individuals. According to Food and Drug administration (FDA), Adverse Drug Reactions are the fourth leading cause of death ahead of pulmonary disease, diabetes, AIDS, pneumonia, accidents. Underreporting of Adverse Drug Reactions is a serious issue hampering the Pharmacovigilance. The Indian Pharmacopoeia Commission (IPC) which acts as the National Coordinating Centre (NCC) for the Pharmacovigilance Programme of India (PvPI) informed that the country?s contribution to WHO-UMC global safety has increased up to 2 per cent in 2013. India is the fifth largest country in Asia and seventh in world highest reporting per cent of ADR to the global safety data base. Most common reasons from the past studies were reported as the perception of reporting process is being tedious, lack of time, having poor knowledge on reporting mechanisms for the success of pharmacovigilance programme and for the better clinical management of the patients in general. Imparting basic and adequate training to health care professionals through nearest pharmacovigilance centers will improve further the problem of under reporting in spontaneous reporting system.

Biography :

Bhavana Akula is student of 4th PharmD (Doctor of Pharmacy) at Annamacharya College of Pharmacy. During her course, shewon second place in scientific session on theme ?Caffiene and Its Risks?. She has attended many of the national workshops mainly regarding Pharmacy practice and clinical trials. She has given presentations on the topics of ?Identification of Allosteric Ligand Binding Sites in Proteins?, ?The Clinical Pharmacist Role in Adverse Drug Reactions? etc. , and presently doing project on the ?Assessing Efficacy of Anti-Retroviral Therapy in Reducing the Risks of Perinatal Transmission?.